1fap › Citations

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.

Choi J, Chen J, Schreiber SL, Clardy J
Science 273 239-42 (1996)
Cited: 511 times
EuropePMC logo PMID: 8662507

Abstract

Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP). A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resolution of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously. The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins. The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects observed for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasia mutant gene product, and it illustrates how a small cell-permeable molecule can mediate protein dimerization.

Reviews - 1fap mentioned but not cited (12)

  1. Modulators of 14-3-3 Protein-Protein Interactions. Stevers LM, Sijbesma E, Botta M, MacKintosh C, Obsil T, Landrieu I, Cau Y, Wilson AJ, Karawajczyk A, Eickhoff J, Davis J, Hann M, O'Mahony G, Doveston RG, Brunsveld L, Ottmann C. J Med Chem 61 3755-3778 (2018)
  2. Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds. Dunyak BM, Gestwicki JE. J Med Chem 59 9622-9644 (2016)
  3. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Hubbard PA, Moody CL, Murali R. Front Physiol 5 478 (2014)
  4. Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs. Shin WH, Kumazawa K, Imai K, Hirokawa T, Kihara D. Adv Appl Bioinform Chem 13 11-25 (2020)
  5. SPLINTS: small-molecule protein ligand interface stabilizers. Fischer ES, Park E, Eck MJ, Thomä NH. Curr Opin Struct Biol 37 115-122 (2016)
  6. Structural Insights into TOR Signaling. Tafur L, Kefauver J, Loewith R. Genes (Basel) 11 E885 (2020)
  7. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Liu H, Qiu W, Sun T, Wang L, Du C, Hu Y, Liu W, Feng F, Chen Y, Sun H. Acta Pharm Sin B 12 1781-1804 (2022)
  8. Chemical strategies to overcome resistance against targeted anticancer therapeutics. Pisa R, Kapoor TM. Nat Chem Biol 16 817-825 (2020)
  9. Overview of Research into mTOR Inhibitors. Mao B, Zhang Q, Ma L, Zhao DS, Zhao P, Yan P. Molecules 27 5295 (2022)
  10. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Expert Opin Investig Drugs 28 583-592 (2019)
  11. Discovering new biology with drug-resistance alleles. Freedy AM, Liau BB. Nat Chem Biol 17 1219-1229 (2021)
  12. Protein-protein interfaces in molecular glue-induced ternary complexes: classification, characterization, and prediction. Rui H, Ashton KS, Min J, Wang C, Potts PR. RSC Chem Biol 4 192-215 (2023)

Articles - 1fap mentioned but not cited (29)



Reviews citing this publication (171)

  1. mTOR: from growth signal integration to cancer, diabetes and ageing. Zoncu R, Efeyan A, Sabatini DM. Nat Rev Mol Cell Biol 12 21-35 (2011)
  2. TOR, a central controller of cell growth. Schmelzle T, Hall MN. Cell 103 253-262 (2000)
  3. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Fingar DC, Blenis J. Oncogene 23 3151-3171 (2004)
  4. Rapamycin passes the torch: a new generation of mTOR inhibitors. Benjamin D, Colombi M, Moroni C, Hall MN. Nat Rev Drug Discov 10 868-880 (2011)
  5. Target of rapamycin (TOR) in nutrient signaling and growth control. Loewith R, Hall MN. Genetics 189 1177-1201 (2011)
  6. The exploration of macrocycles for drug discovery--an underexploited structural class. Driggers EM, Hale SP, Lee J, Terrett NK. Nat Rev Drug Discov 7 608-624 (2008)
  7. Oncogenic PI3K deregulates transcription and translation. Bader AG, Kang S, Zhao L, Vogt PK. Nat Rev Cancer 5 921-929 (2005)
  8. Lessons from natural molecules. Clardy J, Walsh C. Nature 432 829-837 (2004)
  9. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. Clin Biochem 31 335-340 (1998)
  10. Features of selective kinase inhibitors. Knight ZA, Shokat KM. Chem Biol 12 621-637 (2005)
  11. mTOR and cancer therapy. Easton JB, Houghton PJ. Oncogene 25 6436-6446 (2006)
  12. Autophagy: pathways for self-eating in plant cells. Liu Y, Bassham DC. Annu Rev Plant Biol 63 215-237 (2012)
  13. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Tsang CK, Qi H, Liu LF, Zheng XF. Drug Discov Today 12 112-124 (2007)
  14. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Biochem Pharmacol 90 197-207 (2014)
  15. Amino acid regulation of TOR complex 1. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Am J Physiol Endocrinol Metab 296 E592-602 (2009)
  16. The TOR pathway comes of age. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. Biochim Biophys Acta 1790 1067-1074 (2009)
  17. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Crespo JL, Hall MN. Microbiol Mol Biol Rev 66 579-91, table of contents (2002)
  18. New approaches to molecular cancer therapeutics. Collins I, Workman P. Nat Chem Biol 2 689-700 (2006)
  19. Emerging common themes in regulation of PIKKs and PI3Ks. Lempiäinen H, Halazonetis TD. EMBO J 28 3067-3073 (2009)
  20. mTOR in Brain Physiology and Pathologies. Bockaert J, Marin P. Physiol Rev 95 1157-1187 (2015)
  21. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Dunlop EA, Tee AR. Cell Signal 21 827-835 (2009)
  22. The structures of type I polyketide synthases. Keatinge-Clay AT. Nat Prod Rep 29 1050-1073 (2012)
  23. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Zhou H, Huang S. Curr Protein Pept Sci 12 30-42 (2011)
  24. Aggresome formation and neurodegenerative diseases: therapeutic implications. Olzmann JA, Li L, Chin LS. Curr Med Chem 15 47-60 (2008)
  25. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Gibbons JJ, Abraham RT, Yu K. Semin Oncol 36 Suppl 3 S3-S17 (2009)
  26. ATM, a central controller of cellular responses to DNA damage. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. Cell Death Differ 8 1052-1065 (2001)
  27. Identification of direct protein targets of small molecules. Lomenick B, Olsen RW, Huang J. ACS Chem Biol 6 34-46 (2011)
  28. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN. Q Rev Biophys 42 1-40 (2009)
  29. Interfacial inhibitors: targeting macromolecular complexes. Pommier Y, Marchand C. Nat Rev Drug Discov 11 25-36 (2011)
  30. Organ size control by Hippo and TOR pathways. Tumaneng K, Russell RC, Guan KL. Curr Biol 22 R368-79 (2012)
  31. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? King GD, Scott Turner R. Exp Neurol 185 208-219 (2004)
  32. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Hernandez-Aya LF, Gonzalez-Angulo AM. Oncologist 16 404-414 (2011)
  33. Updates of mTOR inhibitors. Zhou H, Luo Y, Huang S. Anticancer Agents Med Chem 10 571-581 (2010)
  34. TOR Complexes and the Maintenance of Cellular Homeostasis. Eltschinger S, Loewith R. Trends Cell Biol 26 148-159 (2016)
  35. Mechanisms of mTOR inhibitor resistance in cancer therapy. Carew JS, Kelly KR, Nawrocki ST. Target Oncol 6 17-27 (2011)
  36. Targeting protein-protein interaction by small molecules. Jin L, Wang W, Fang G. Annu Rev Pharmacol Toxicol 54 435-456 (2014)
  37. Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Bruntz RC, Lindsley CW, Brown HA. Pharmacol Rev 66 1033-1079 (2014)
  38. Protein translocation as a tool: The current rapamycin story. Putyrski M, Schultz C. FEBS Lett 586 2097-2105 (2012)
  39. Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases. Hyttinen JM, Amadio M, Viiri J, Pascale A, Salminen A, Kaarniranta K. Ageing Res Rev 18 16-28 (2014)
  40. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Vilar E, Perez-Garcia J, Tabernero J. Mol Cancer Ther 10 395-403 (2011)
  41. Industrial natural product chemistry for drug discovery and development. Bauer A, Brönstrup M. Nat Prod Rep 31 35-60 (2014)
  42. The complexes of mammalian target of rapamycin. Zhou H, Huang S. Curr Protein Pept Sci 11 409-424 (2010)
  43. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Russell RC, Fang C, Guan KL. Development 138 3343-3356 (2011)
  44. Nutrient sensing and metabolic decisions. Lindsley JE, Rutter J. Comp Biochem Physiol B Biochem Mol Biol 139 543-559 (2004)
  45. mTOR inhibitors in the treatment of cancer. Fasolo A, Sessa C. Expert Opin Investig Drugs 17 1717-1734 (2008)
  46. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Pommier Y, Cherfils J. Trends Pharmacol Sci 26 138-145 (2005)
  47. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP, Krueger DA. Neuro Oncol 17 1550-1559 (2015)
  48. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Thiel P, Kaiser M, Ottmann C. Angew Chem Int Ed Engl 51 2012-2018 (2012)
  49. Insights into the mechanisms of eukaryotic translation gained with ribosome profiling. Andreev DE, O'Connor PB, Loughran G, Dmitriev SE, Baranov PV, Shatsky IN. Nucleic Acids Res 45 513-526 (2017)
  50. Current development of the second generation of mTOR inhibitors as anticancer agents. Zhou HY, Huang SL. Chin J Cancer 31 8-18 (2012)
  51. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Hughes SJ, Ciulli A. Essays Biochem 61 505-516 (2017)
  52. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Chen J, Fang Y. Biochem Pharmacol 64 1071-1077 (2002)
  53. Immunophilins: switched on protein binding domains? Ivery MT. Med Res Rev 20 452-484 (2000)
  54. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D. Leukemia 24 1686-1699 (2010)
  55. mTOR function and therapeutic targeting in breast cancer. Hare SH, Harvey AJ. Am J Cancer Res 7 383-404 (2017)
  56. Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G. Front Pharmacol 7 395 (2016)
  57. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J. Clin Microbiol Rev 12 583-611 (1999)
  58. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Villalobos V, Naik S, Piwnica-Worms D. Annu Rev Biomed Eng 9 321-349 (2007)
  59. Mammalian target of rapamycin as a therapeutic target in oncology. Abraham RT, Eng CH. Expert Opin Ther Targets 12 209-222 (2008)
  60. Conditional Degrons for Controlling Protein Expression at the Protein Level. Natsume T, Kanemaki MT. Annu Rev Genet 51 83-102 (2017)
  61. Influence of mTOR in energy and metabolic homeostasis. Haissaguerre M, Saucisse N, Cota D. Mol Cell Endocrinol 397 67-77 (2014)
  62. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Santulli G, Totary-Jain H. Pharmacogenomics 14 1517-1526 (2013)
  63. Therapeutic potential of target of rapamycin inhibitors. Easton JB, Houghton PJ. Expert Opin Ther Targets 8 551-564 (2004)
  64. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL. Q Rev Biophys 45 383-426 (2012)
  65. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. García-Echeverría C. Bioorg Med Chem Lett 20 4308-4312 (2010)
  66. Cancer and mTOR Inhibitors in Transplant Recipients. de Fijter JW. Transplantation 101 45-55 (2017)
  67. Mammalian target of rapamycin and the kidney. I. The signaling pathway. Lieberthal W, Levine JS. Am J Physiol Renal Physiol 303 F1-10 (2012)
  68. mTOR signaling in cancer cell motility and tumor metastasis. Zhou H, Huang S. Crit Rev Eukaryot Gene Expr 20 1-16 (2010)
  69. Pipecolic acid in microbes: biosynthetic routes and enzymes. He M. J Ind Microbiol Biotechnol 33 401-407 (2006)
  70. mTOR signaling in autophagy regulation in the kidney. Inoki K. Semin Nephrol 34 2-8 (2014)
  71. mTOR-Dependent Cell Proliferation in the Brain. Ryskalin L, Lazzeri G, Flaibani M, Biagioni F, Gambardella S, Frati A, Fornai F. Biomed Res Int 2017 7082696 (2017)
  72. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. Caron A, Briscoe DM, Richard D, Laplante M. Physiol Rev 98 1765-1803 (2018)
  73. mTOR signalling in human cancer. Albanell J, Dalmases A, Rovira A, Rojo F. Clin Transl Oncol 9 484-493 (2007)
  74. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. World J Gastroenterol 21 12059-12070 (2015)
  75. The PIK-related kinases intercept conventional signaling pathways. Kuruvilla FG, Schreiber SL. Chem Biol 6 R129-36 (1999)
  76. Current and future directions in mammalian target of rapamycin inhibitors development. Fasolo A, Sessa C. Expert Opin Investig Drugs 20 381-394 (2011)
  77. mTOR Inhibition: From Aging to Autism and Beyond. Kaeberlein M. Scientifica (Cairo) 2013 849186 (2013)
  78. mTOR in health and in sickness. Liko D, Hall MN. J Mol Med (Berl) 93 1061-1073 (2015)
  79. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. Jhanwar-Uniyal M, Jeevan D, Neil J, Shannon C, Albert L, Murali R. Adv Biol Regul 53 202-210 (2013)
  80. m-TOR inhibitors and their potential role in haematological malignancies. Calimeri T, Ferreri AJM. Br J Haematol 177 684-702 (2017)
  81. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. Statz CM, Patterson SE, Mockus SM. Target Oncol 12 47-59 (2017)
  82. Current status and challenges associated with targeting mTOR for cancer therapy. Dowling RJ, Pollak M, Sonenberg N. BioDrugs 23 77-91 (2009)
  83. Natural product-like chemical space: search for chemical dissectors of macromolecular interactions. Reayi A, Arya P. Curr Opin Chem Biol 9 240-247 (2005)
  84. Lysosomal Regulation of mTORC1 by Amino Acids in Mammalian Cells. Yao Y, Jones E, Inoki K. Biomolecules 7 E51 (2017)
  85. Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Graziani EI. Nat Prod Rep 26 602-609 (2009)
  86. Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. Ricci JE, Chiche J. Front Oncol 8 556 (2018)
  87. The structural basis for mTOR function. Baretić D, Williams RL. Semin Cell Dev Biol 36 91-101 (2014)
  88. Genetic and genomic approaches to identify and study the targets of bioactive small molecules. Zheng XS, Chan TF, Zhou HH. Chem Biol 11 609-618 (2004)
  89. Targeted therapies for advanced non-small cell lung cancer. Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhang D, Zhu S. Oncotarget 9 37589-37607 (2018)
  90. The TOR Signaling Network in the Model Unicellular Green Alga Chlamydomonas reinhardtii. Pérez-Pérez ME, Couso I, Crespo JL. Biomolecules 7 E54 (2017)
  91. Current models of mammalian target of rapamycin complex 1 (mTORC1) activation by growth factors and amino acids. Zheng X, Liang Y, He Q, Yao R, Bao W, Bao L, Wang Y, Wang Z. Int J Mol Sci 15 20753-20769 (2014)
  92. Mammalian target of rapamycin signaling in the podocyte. Inoki K, Huber TB. Curr Opin Nephrol Hypertens 21 251-257 (2012)
  93. Role of mTOR inhibitors in epilepsy treatment. Sadowski K, Kotulska-Jóźwiak K, Jóźwiak S. Pharmacol Rep 67 636-646 (2015)
  94. Auxin Signaling in Regulation of Plant Translation Reinitiation. Schepetilnikov M, Ryabova LA. Front Plant Sci 8 1014 (2017)
  95. Current Approaches and Future Directions for the Treatment of mTORopathies. Karalis V, Bateup HS. Dev Neurosci 43 143-158 (2021)
  96. Drug Inducible CRISPR/Cas Systems. Zhang J, Chen L, Zhang J, Wang Y. Comput Struct Biotechnol J 17 1171-1177 (2019)
  97. Inhibiting 4EBP1 in Glioblastoma. Fan QW, Nicolaides TP, Weiss WA. Clin Cancer Res 24 14-21 (2018)
  98. Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality. Kostic M, Jones LH. Trends Pharmacol Sci 41 305-317 (2020)
  99. Evolution of TOR-SnRK dynamics in green plants and its integration with phytohormone signaling networks. Jamsheer K M, Jindal S, Laxmi A. J Exp Bot 70 2239-2259 (2019)
  100. Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands. Galat A. Cell Mol Life Sci 70 3243-3275 (2013)
  101. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies. Heeres JT, Hergenrother PJ. Chem Soc Rev 40 4398-4410 (2011)
  102. Targeting mTOR for the treatment of B cell malignancies. Lee JS, Vo TT, Fruman DA. Br J Clin Pharmacol 82 1213-1228 (2016)
  103. The chemical biology of phosphoinositide 3-kinases. Wymann MP, Schultz C. Chembiochem 13 2022-2035 (2012)
  104. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S. Target Oncol 7 173-181 (2012)
  105. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Dhillon S. Drugs 73 475-485 (2013)
  106. Switchable inteins for conditional protein splicing. Di Ventura B, Mootz HD. Biol Chem 400 467-475 (2019)
  107. The role of mTOR in age-related diseases. Chrienova Z, Nepovimova E, Kuca K. J Enzyme Inhib Med Chem 36 1679-1693 (2021)
  108. Proximity labeling: an emerging tool for probing in planta molecular interactions. Yang X, Wen Z, Zhang D, Li Z, Li D, Nagalakshmi U, Dinesh-Kumar SP, Zhang Y. Plant Commun 2 100137 (2021)
  109. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Camardo J. Transplant Proc 35 18S-24S (2003)
  110. DEPDC5 as a potential therapeutic target for epilepsy. Myers KA, Scheffer IE. Expert Opin Ther Targets 21 591-600 (2017)
  111. Stabilization of protein-protein interactions by small molecules. Giordanetto F, Schäfer A, Ottmann C. Drug Discov Today 19 1812-1821 (2014)
  112. The emerging role of large immunophilin FK506 binding protein 51 in cancer. Romano S, Sorrentino A, Di Pace AL, Nappo G, Mercogliano C, Romano MF. Curr Med Chem 18 5424-5429 (2011)
  113. Blocking the mTOR pathway: a drug discovery perspective. Garcia-Echeverria C. Biochem Soc Trans 39 451-455 (2011)
  114. Spatial regulation of the mTORC1 system in amino acids sensing pathway. Suzuki T, Inoki K. Acta Biochim Biophys Sin (Shanghai) 43 671-679 (2011)
  115. mTOR Inhibitors in Advanced Biliary Tract Cancers. Wu CE, Chen MH, Yeh CN. Int J Mol Sci 20 E500 (2019)
  116. Amino acid sensing and regulation of mTORC1. Yan L, Lamb RF. Semin Cell Dev Biol 23 621-625 (2012)
  117. Target of Rapamycin in Control of Autophagy: Puppet Master and Signal Integrator. Mugume Y, Kazibwe Z, Bassham DC. Int J Mol Sci 21 E8259 (2020)
  118. Ligand-directed tosyl chemistry for in situ native protein labeling and engineering in living systems: from basic properties to applications. Tsukiji S, Hamachi I. Curr Opin Chem Biol 21 136-143 (2014)
  119. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors Beyens M, Vandamme T, Peeters M, Van Camp G, Op de Beeck K. Endocr Relat Cancer 26 R109-R130 (2019)
  120. Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Holloway RW, Marignani PA. Cancers (Basel) 13 2922 (2021)
  121. Protein tango: the toolbox to capture interacting partners. Rutkowska A, Schultz C. Angew Chem Int Ed Engl 51 8166-8176 (2012)
  122. Some conditions apply: Systems for studying Plasmodium falciparum protein function. Kudyba HM, Cobb DW, Vega-Rodríguez J, Muralidharan V. PLoS Pathog 17 e1009442 (2021)
  123. mTOR signaling in lymphangioleiomyomatosis. Kristof AS. Lymphat Res Biol 8 33-42 (2010)
  124. Calcineurin-immunosuppressor complexes. Stoddard BL, Flick KE. Curr Opin Struct Biol 6 770-775 (1996)
  125. FK506-binding protein 12 ligands: a patent review. Liu F, Wang YQ, Meng L, Gu M, Tan RY. Expert Opin Ther Pat 23 1435-1449 (2013)
  126. Overcoming resistance to rapalogs in gliomas by combinatory therapies. Grzmil M, Hemmings BA. Biochim Biophys Acta 1834 1371-1380 (2013)
  127. TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. Song Y, Buchwald P. Curr Drug Targets 16 393-408 (2015)
  128. Target of rapamycin, a master regulator of multiple signalling pathways and a potential candidate gene for crop improvement. Bakshi A, Moin M, Madhav MS, Kirti PB. Plant Biol (Stuttg) 21 190-205 (2019)
  129. Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. Benn CL, Dawson LA. Front Aging Neurosci 12 242 (2020)
  130. Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders. Soo SK, Rudich PD, Traa A, Harris-Gauthier N, Shields HJ, Van Raamsdonk JM. Mech Ageing Dev 190 111297 (2020)
  131. Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease. Lim KG, Gray AI, Anthony NG, Mackay SP, Pyne S, Pyne NJ. Arch Toxicol 88 2213-2232 (2014)
  132. TOR inhibitors: from mammalian outcomes to pharmacogenetics in plants and algae. Montané MH, Menand B. J Exp Bot 70 2297-2312 (2019)
  133. Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief. Rouwette T, Avenali L, Sondermann J, Narayanan P, Gomez-Varela D, Schmidt M. Channels (Austin) 9 175-185 (2015)
  134. Regulation of the Target of Rapamycin and Other Phosphatidylinositol 3-Kinase-Related Kinases by Membrane Targeting. De Cicco M, Rahim MS, Dames SA. Membranes (Basel) 5 553-575 (2015)
  135. Small molecules, peptides and natural products: getting a grip on 14-3-3 protein-protein modulation. Bartel M, Schäfer A, Stevers LM, Ottmann C. Future Med Chem 6 903-921 (2014)
  136. Three-dimensional structural labeling microscopy of cilia and flagella. Oda T. Microscopy (Oxf) 66 234-244 (2017)
  137. Targeting protein function: the expanding toolkit for conditional disruption. Campbell AE, Bennett D. Biochem J 473 2573-2589 (2016)
  138. The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. Kim HJ, Lee SY, Oh SC. Front Physiol 7 168 (2016)
  139. Unraveling the multifaceted nature of the nuclear function of mTOR. Torres AS, Holz MK. Biochim Biophys Acta Mol Cell Res 1868 118907 (2021)
  140. An overview of kinase downregulators and recent advances in discovery approaches. Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. Signal Transduct Target Ther 6 423 (2021)
  141. Synthesis and biological evaluation of rapamycin-derived, next generation small molecules. Guduru SKR, Arya P. Medchemcomm 9 27-43 (2018)
  142. The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells. Yao Y, Inoki K. Curr Opin Nephrol Hypertens 25 28-34 (2016)
  143. Points of View on the Tools for Genome/Gene Editing. Chuang CK, Lin WM. Int J Mol Sci 22 9872 (2021)
  144. Protein-drug complexes important for immunoregulation and organ transplantation. Navia MA. Curr Opin Struct Biol 6 838-847 (1996)
  145. Drosophila as a Model Organism to Study Basic Mechanisms of Longevity. Ogienko AA, Omelina ES, Bylino OV, Batin MA, Georgiev PG, Pindyurin AV. Int J Mol Sci 23 11244 (2022)
  146. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy. Rochani AK, Ravindran Girija A, Borah A, Maekawa T, Sakthi Kumar D. J Pharm Sci 105 1454-1466 (2016)
  147. Influenza antivirals and animal models. Caceres CJ, Seibert B, Cargnin Faccin F, Cardenas-Garcia S, Rajao DS, Perez DR. FEBS Open Bio 12 1142-1165 (2022)
  148. Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016). Xiu C, Hua Z, Xiao BS, Tang WJ, Zhou HP, Liu XH. Expert Opin Ther Pat 27 1031-1045 (2017)
  149. Regulation of Hematopoietic Stem Cell Fate and Malignancy. Cho HJ, Lee J, Yoon SR, Lee HG, Jung H. Int J Mol Sci 21 E4780 (2020)
  150. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Fernandes-Silva G, Ivani de Paula M, Rangel ÉB. Expert Opin Drug Metab Toxicol 13 367-385 (2017)
  151. David and Goliath: chemical perturbation of eukaryotes by bacteria. Ho LK, Nodwell JR. J Ind Microbiol Biotechnol 43 233-248 (2016)
  152. New experimental trends for phosphoinositides research on ion transporter/channel regulation. Mori MX, Inoue R. J Pharmacol Sci 126 186-197 (2014)
  153. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Vincenzi B, Napolitano A, D'Onofrio L, Frezza AM, Silletta M, Venditti O, Santini D, Tonini G. Expert Opin Investig Drugs 20 1685-1705 (2011)
  154. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Goul C, Peruzzo R, Zoncu R. Nat Rev Mol Cell Biol 24 857-875 (2023)
  155. Chemical and Structural Strategies to Selectively Target mTOR Kinase. Borsari C, De Pascale M, Wymann MP. ChemMedChem 16 2744-2759 (2021)
  156. Chemical tools for dissecting cell division. Chen GY, Lampson MA. Nat Chem Biol 17 632-640 (2021)
  157. Chemogenetics of cell surface receptors: beyond genetic and pharmacological approaches. Miura Y, Senoo A, Doura T, Kiyonaka S. RSC Chem Biol 3 269-287 (2022)
  158. Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus. Ganesh SK, Subathra Devi C. Mol Biol Rep 50 3815-3833 (2023)
  159. Utilization of kinase inhibitors as novel therapeutic drug targets: A review. Nishal S, Jhawat V, Gupta S, Phaugat P. Oncol Res 30 221-230 (2022)
  160. Analysis of the Selective Antagonist SAFit2 as a Chemical Probe for the FK506-Binding Protein 51. Buffa V, Knaup FH, Heymann T, Springer M, Schmidt MV, Hausch F. ACS Pharmacol Transl Sci 6 361-371 (2023)
  161. Molecular Approaches to Protein Dimerization: Opportunities for Supramolecular Chemistry. Dang DT. Front Chem 10 829312 (2022)
  162. Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities. Galat A. Biomolecules 7 E72 (2017)
  163. Rational design of small-molecule responsive protein switches. Shui S, Buckley S, Scheller L, Correia BE. Protein Sci 32 e4774 (2023)
  164. Regulation of mTOR by phosphatidic acid. Frias MA, Hatipoglu A, Foster DA. Trends Endocrinol Metab 34 170-180 (2023)
  165. Substrate-selective small-molecule modulators of enzymes: Mechanisms and opportunities. Lin H. Curr Opin Chem Biol 72 102231 (2023)
  166. Localised interventions in cellular processes. Peel N, Larijani B, Parker PJ. Biochim Biophys Acta 1834 1364-1370 (2013)
  167. Molecular chameleons in drug discovery. Poongavanam V, Wieske LHE, Peintner S, Erdélyi M, Kihlberg J. Nat Rev Chem 8 45-60 (2024)
  168. Reverse-ChIP Techniques for Identifying Locus-Specific Proteomes: A Key Tool in Unlocking the Cancer Regulome. MacKenzie TMG, Cisneros R, Maynard RD, Snyder MP. Cells 12 1860 (2023)
  169. Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results. Thervet E. Int J Nanomedicine 1 269-281 (2006)
  170. The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. Lee MTW, Mahy W, Rackham MD. RSC Med Chem 12 1281-1311 (2021)
  171. Yeast Crf1p: An activator in need is an activator indeed. Kumar S, Mashkoor M, Grove A. Comput Struct Biotechnol J 20 107-116 (2022)

Articles citing this publication (299)



Quick links